AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02308696 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Peer-to-Peer Support
Description: All three data collection sites run peer-to-peer community support programs. Core program elements include the same program objective, standard definition of who qualifies for peer-to-peer support, the mechanism by which older adults are referred for consideration for peer-support, core elements of training programs for the older adults who volunteer to provide the peer support, and monthly in-service trainings for all volunteers once trained, weekly hours that volunteers spend providing support, and provision of small stipends for volunteers.As they find their role very rewarding, there is very little peer turn-over; the vast majority of peers volunteer for years in this role, until they themselves start requiring services.
Study NCT02308696 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Community Services
Description: All three data collection sites will continue to provide standard community services to the older adults that are not enrolled in the peer-to-peer support program
Study NCT02279277 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Supervised physical therapy program prior to total knee replacement surgery
Study NCT00905541 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: simvastatin
Description: 40 mg/day
Study NCT00905541 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: simvastatin
Description: 80 mg simvastatin acute-on-chronic
Study NCT03232450 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Aspirin
Description: Subjects will receive 81 mg enteric coated aspirin
Study NCT03232450 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin
Description: Subjects will receive 81 mg enteric coated aspirin
Study NCT03232450 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Cardiovascular Implantable Device (CIED)
Description: All subjects will receive either a pacemaker, implantable cardioverter-defibrillator (ICD), or cardiac resynchronization therapy (CRT).
Study NCT03232450 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cardiovascular Implantable Device (CIED)
Description: All subjects will receive either a pacemaker, implantable cardioverter-defibrillator (ICD), or cardiac resynchronization therapy (CRT).
Study NCT03232450 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Gore Cardioform Septal Occluder
Description: The Gore Cardioform Septal Occluder closes the patent foramen ovale (PFO).
Study NCT02218541 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: abutment margin 0.5 mm subgingival
Study NCT02218541 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: abutment margin 1.5 mm subgingival
Study NCT04965233 — intervention group
Intervention type: BEHAVIORAL
Intervention: DNA reports
Description: The personalized DNA lifestyle reports cover the following topics: Healthy weight, Vitamin D, Alcohol, Lactose, Injuries, Caffeine, Fitness, Carbohydrates, The mind, Vitamin B, The senses, and Omega.
Study NCT04965233 — intervention group
Intervention type: BEHAVIORAL
Intervention: Information reports
Description: Reports containing general information on eczema
Study NCT05055687 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FL058
Description: 2500mg、3000mg
Study NCT05055687 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: empty bottle
Study NCT05055687 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FL058
Description: 500mg、1000mg、2000mg
Study NCT03599583 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: STOP-HPV prompts intervention
Description: This intervention will be the addition of the prompts intervention (in the presence of communication skills training and continued performance feedback).
Study NCT03256864 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus and Everolimus
Description: In the TAC and EVR BID arm, everolimus will be initiated at a dose of 1.0 mg BID within 24 h of randomization with the dose adjusted from day 5 onward to maintain trough (C0) concentration in the range 3-8 ng/mL. Tacrolimus will be initiated at a dose of 0.15 mg/kg BID and then taper to 0.10 mg/kg BID to maintain trough (C0) concentration in the range 2.5-5 ng/mL.~In the TAC and EVR QD arm, everolimus will be initiated at a dose of 2.0 mg QD within 24 h of randomization with the dose adjusted from day 5 onward to maintain trough (C0) concentration in the range 3-8 ng/mL. Tacrolimus will be initiated at a dose of 0.1-0.2 mg/kg/day QD to maintain trough (C0) concentration in the range 2.5-5 ng/mL.
Study NCT00405262 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketorolac
Description: 0.5 mg•kg-1 IV at the end of surgery before extubation and then 3 additional doses every 8 hours thereafter
Study NCT00405262 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine
Description: 0.2 mL•kg-1 (lean body mass) bolus of bupivacaine 0.25% with epinephrine 1:200 000 will be injected through the IC catheter at the end surgery before the patient's trachea is extubated to detect intravascular injection. An infusion of the same solution will be started at 0.1 mL•kg-1•hour-1 (lean body mass) for 24 hours.
Study NCT00405262 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ketorolac + bupivacaine
Description: 0.2 mL•kg-1 (lean body mass) bolus of bupivacaine 0.25% with epinephrine 1:200 000 will be injected through the IC catheter at the end surgery before the patient's trachea is extubated to detect intravascular injection. An infusion of the same solution will be started at 0.1 mL•kg-1•hour-1 (lean body mass) for 24 hours.~For ketorolac, patients will receive 0.5 mg•kg-1 IV at the end of surgery before extubation and then 3 additional doses every 8 hours thereafter
Study NCT01756313 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laser+Methylaminolevulinat
Description: It's a single arm study. Intervention as described in detailed description.
Study NCT03314857 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SAPIEN XT THV with the NovaFlex+ delivery system
Description: Edwards SAPIEN XT™ Transcatheter Heart Valve along with NovaFlex+ delivery system
Study NCT01202253 — intervention group
Intervention type: DRUG
Intervention: anidulafungin
Description: A single 200 mg loading dose should be administered on Day 1, followed by 100 mg daily thereafter.
Study NCT02901730 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 532nm laser group
Description: LPI with 532nm laser.
Study NCT02901730 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 561nm laser group
Description: LPI with 561nm laser.
Study NCT04133116 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3471851
Description: Administered SC
Study NCT04133116 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered SC
Study NCT03329924 — intervention group
Intervention type: OTHER
Intervention: Activity level measurement by accelerometer
Description: Eligible patients will wear an accelerometer to measure activity levels while in the ICU.
Study NCT02299869 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Verde (Competitor-control)
Description: contact lens
Study NCT02299869 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Green (CVI-test)
Description: contact lens
Study NCT02299869 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Cinza (Competitor-control)
Description: contact lens
Study NCT02299869 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Grey (CVI-test)
Description: contact lens
Study NCT02299869 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Esmeralda (Competitor-control)
Description: contact lens
Study NCT02299869 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Jade (CVI-test)
Description: contact lens
Study NCT01837147 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Technology-Based Physical Activity Promotion
Description: Participants assigned to this group will use a web-integrated physical activity monitor, and accompanying website, to improve their physical activity levels.
Study NCT01837147 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Pedometer Intervention
Description: Participants assigned to this group will receive a pedometer and be trained in its use.
Study NCT04004507 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phentolamine Mesylate Ophthalmic Solution 1%
Description: Topical Sterile Ophthalmic Solution
Study NCT04004507 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Phentolamine Mesylate Ophthalmic Solution Vehicle (Placebo)
Description: Topical Sterile Ophthalmic Solution
Study NCT06235164 — intervention group
Intervention type: DRUG
Intervention: immune checkpoint inhibitors: sintilimab, nivolumab, and camrelizumab
Description: Drug: Sintilimab, Nivolumab, and Camrelizumab，One course will last 21 days.Given once every 3 weeks at a dose of 200 mg. Drug: nab-paclitaxel nab-paclitaxel one course will last 21 days#Given twice every 3 weeks at a dose of 125 mg/m2. Drug:oxaliplatin Oxaliplatin one course will last 21 days#Given once every 3 weeks at a dose of 130 mg/m2.~Drug:docetaxel docetaxel one course will last 21 days#Given once every 3 weeks at a dose of 40mg/m2.~Drug:fluorouracil fluorouracil one course will last 14 days#Given once every 2 weeks at a dose of 2800mg/m2.~Drug: Capecitabine Capecitabine was calculated according to body surface area every 3 weeks at a dose of 1000 mg/m2, P.O., bid, d1-d14 Drug: S1 S-1 was calculated according to body surface area, P.O., bid, d1-d14#And the dosage according body surface area:\<1.25m2, 40mg everytime;1.25-1.5m2,50mg every time; >1.5m2, 60mg every time
Study NCT03928561 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active intense Pure Air XL air cleaner
Description: Cat allergen is nebulized in the EEC. When the concentration is stable, air cleaners are switched on. The number of air cleaners placed in the EEC is defined according to the volume of the EEC and the air renewal. Patients are exposed to cat allergen in the presence of active air cleaners in the EEC
Study NCT03928561 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Placebo Intense Pure Air XL air cleaner
Description: Cat allergen is nebulized in the EEC. When the concentration is stable, placebo air cleaners are switched on. The placebo effect is obtained thanks to the removal of air cleaners filters prior to the exposure. The number of placebo air cleaners placed in the EEC is defined according to the volume of the EEC and the air renewal. Patients are exposed to cat allergen in the presence of placebo air cleaners in the EEC.
Study NCT01079455 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Corticosterone
Description: Hyaluronic acid 40 mg / 2 ml Corticosteroids 80 mg / 2 ml Bupivacaine 0.125% / 2 ml
Study NCT00870272 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Misoprostol
Description: 400mcg misoprostol taken sublingually or buccally
Study NCT00478972 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rimonabant
Description: Tablet, oral administration
Study NCT01079455 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Corticosterone
Description: Hyaluronic acid 40 mg / 2 ml Corticosteroids 80 mg / 2 ml Bupivacaine 0.125% / 2 ml
Study NCT00478972 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo (for Rimonabant)
Description: Tablet, oral administration
Study NCT00478972 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Diet and exercise
Description: Target daily caloric intake: Ideal body weight × 25 kcal
Study NCT00478972 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diet and exercise
Description: Target daily caloric intake: Ideal body weight × 25 kcal
Study NCT01270646 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Invasive mapping with CARTO3 system and Non-Invasive mapping with CardioInsight Atlas EC Mapping system
Description: Day 1: CRT device is implanted under general anesthesia in a conventional fashion. The coronary sinus leads will be implanted guided by the acute hemodynamic response (+(dP/dt)max) using a RADI guide wire. After device implantation, a steerable mapping catheter will be inserted in the Left Ventricle (LV) cavity to build a tridimensional activation map of the LV. This map will be obtained with and without CRT. From these maps different parameters describing LV activation will be measured and compared between patients with and without CRT.~Day 5±2: A non-invasive map of the LV will be recorded with the CardioInsight ® system with and without CRT. The same parameters will be measured and compared with those obtained with invasive mapping.
Study NCT03809065 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitroglycerin
Description: Nitroglycerin is a direct vasodilator and its main action is through venodilation. Nitroglycerin will be diluted by adding 3 mL (3 mg) to 47 mL normal saline in a 50 mL syringe and will be infused after endotracheal intubation with a starting dose of 0.5 mL/Kg/ hr to have a starting dose of 0.5 μg/Kg/min. The rate of nitroglycerin infusion will be 0.5-2 μg /kg/min .The infusion rate will be finely adjusted to maintain MAP around 55-65mmHg or till reaching adequate surgical field {defined as surgical field score (SFS) \<3}.
Study NCT03809065 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Labetalol
Description: Labetalol is an α and β - adrenergic receptors competitive antagonist. Labetalol will be diluted by adding 10 mL (50 mg) to 40 mL normal saline in a 50 mL syringe and will be infused after endotracheal intubation with a starting dose of 0.5 mL/Kg/ hr. The rate of Labetalol infusion will be 0.5-2 mg/kg/h.The infusion rate will be finely adjusted to maintain MAP around 55-65mmHg or till reaching adequate surgical field {defined as surgical field score (SFS) \<3}.
Study NCT02083250 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Allogeneic Bone Marrow Transplantation
Description: Undergo allogeneic peripheral blood stem cell or bone marrow transplant
Study NCT02083250 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Allogeneic Hematopoietic Stem Cell Transplantation
Description: Undergo allogeneic peripheral blood stem cell or bone marrow transplant
Study NCT02083250 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Anti-Thymocyte Globulin
Description: Given IV
Study NCT02083250 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Busulfan
Description: Given IV
Study NCT02083250 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clofarabine
Description: Given IV
Study NCT02083250 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine Phosphate
Description: Given IV
Study NCT02083250 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Peripheral Blood Stem Cell Transplantation
Description: Undergo allogeneic peripheral blood stem cell or bone marrow transplant
Study NCT02083250 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies
Study NCT02083250 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vorinostat
Description: Given PO
Study NCT03327922 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vicryl absorbable suture
Description: Vicryl absorbable suture is a synthetic sterile surgical suture made up of a copolymer
Study NCT02116972 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FX006 32 mg
Description: Single 5 mL IA injection
Study NCT03738579 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Next Science Group
Description: TorrentX Wound Wash will be used for irrigation and then BlastX Wound Gel will be applied to the wound after debridement/irrigation during in-clinic visits. BlastX Wound Gel will be re-applied again during mid-week dressing change. Dressing used will be plain foam dressing from control group arm.
Study NCT03738579 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Control Group
Description: Foam Dressing will be used in conjunction with standard of care for chronic wound management, such as debridement and irrigation.
Study NCT03738579 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Antibacterial Control Group
Description: Foam Dressing AG will be used in conjunction with standard of care for chronic wound management, such as debridement and irrigation.
Study NCT02116972 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single 5 mL IA injection
Study NCT02116972 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FX006 16 mg
Description: Single 5 mL IA injection
Study NCT01573208 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Custom guides
Description: Symbios custom guides for TKA
Study NCT00719732 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ReSTOR
Description: Enrolled subjects receive implantation of ReSTOR +3 intraocular lenses (IOLs) for replacement of cataract in the natural lens of the eye. The patients were to be implanted bilaterally (in both eyes).
Study NCT02092415 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Application of a Junctional Tourniquet
Description: All subjects will be studied at baseline and after placement of a junctional tourniquet to the femoral artery.
Study NCT04267653 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lactoferrin Bovine
Description: treatment for 30 days
Study NCT04024683 — intervention group
Intervention type: PROCEDURE
Intervention: Serratus block with ropivacaine 2mg/ml
Description: The serratus block was made using a 50 mm needle with ultrasound guidance. It was performed supine, the ultrasound probe identifying the 3, 4 or 5th intercostal space and then the needle was introduced under ultrasound control
Study NCT02676349 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: mFolfirinox
Description: oxaliplatin folinic acid irinotecan 5FU oxaliplatin
Study NCT02676349 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mFolfirinox
Description: oxaliplatin folinic acid irinotecan 5FU oxaliplatin
Study NCT02676349 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Chemoradiotherapy
Description: conformational external irradiation (50.4 Gy) + capecitabine
Study NCT02676349 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: surgery
Description: 1 to 4 weeks after neoadjuvant treatment according to tumour response
Study NCT02676349 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: surgery
Description: 1 to 4 weeks after neoadjuvant treatment according to tumour response
Study NCT02676349 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adjuvant chemotherapy
Description: Gemcitabine or modified LV5FU (folinic acid+-bolus fluorouracil+ infusional fluorouracil)
Study NCT02676349 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy
Description: Gemcitabine or modified LV5FU (folinic acid+-bolus fluorouracil+ infusional fluorouracil)
Study NCT04267653 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ferrous Sulfate
Description: treatment for 30 days
Study NCT02949310 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nefopam
Study NCT02949310 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Study NCT02584790 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Laryngoscope with NBI system
Description: All post-radiotherapy 8 weeks NPC patient will routinely undergo laryngoscope examination (WL system) and NP biopsy will be taken at the same time to determine if there is any residual NPC. In this study, laryngoscope with NBI system will be used. NBI system will be turn on during the post radiotherapy 8 week laryngoscope examination in additional to routine WL system
Study NCT02542514 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Description: p.o. 560 mg once a day (four 140 mg capsules) for one year (12 cycles of 28 days)
Study NCT03750110 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Intervention
Description: In addition to usual care, personalised feedback from the participants screening appointment will be provided;~* For participants with emphysema, an image of their own emphysematous lung compared to a library image of normal lung, or a section of their own non-emphysematous lung. Where emphysema is not present, library pictures showing normal and emphysematous lung will be used.~* For participants with coronary artery calcification, a cross sectional segment from their chest scan (either horizontal or vertical) showing the calcium compared to a library image of coronary arteries without calcification and/or a healthy section of the participant's own heart scan. Where coronary artery calcification is not present, library pictures showing normal and calcified coronary arteries will be provided.
Study NCT03750110 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Smoking cessation support in line with NICE PH48 guidelines
Study NCT04099901 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anakinra
Description: Subjects will be treated with a daily dose of 300 mg anakinra, intravenously, starting on day -2, until day +12 (day 0 is day of SCT).
Study NCT04099901 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: Subjects will be treated with a daily dose of placebo, intravenously, starting on day -2, until day +12 (day 0 is day of SCT).
Study NCT01924065 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cardioversion
Description: Electrical cardioversion